News and Trends 30 Sep 2019Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin treatment development deal has finished… September 30, 2019 - 4 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jul 2019The Top 10 Biotechs You’ll Find in Lyon Lyon is one of the hotspots for biotech in Europe. Here are 10 of the most successful biotech companies in… July 10, 2019 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 11 Mar 2019The Three Steps Needed to Fully Automate the Artificial Pancreas New advances in diabetes research are making it possible to develop a fully automated insulin delivery system that can control… March 11, 2019 - 11 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2018Insulin Combo Reduces After-Meal Sugar Spikes in Type 1 Diabetics In the midst of a legal litigation with Eli Lilly, Adocia has released Phase 1 data showing its insulin combo… September 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Apr 2018French Double-Hormone Diabetes Treatment to be Tested in Humans for the First Time Adocia, a French biotech, will initiate a Phase I clinical study to test a diabetes treatment that maximizes the effect… April 16, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2017French Biotech’s Type 1 Diabetes Candidate Ready to Battle it Out with Big Pharma Adocia’s rapid-action insulin outperforms Novo Nordisk’s market approved treatment for type 1 diabetes during a Phase I study. Adocia specializes… December 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2017Can this French Biotech Make it Easier to Rescue People from Hypoglycemia? Adocia's ready-to-use glucagon has proved to be safe in phase I trials. The company believes it can overthrow Novo Nordisk… November 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jan 2017Bad News for Diabetics: Eli Lilly Abandons French Ultra-Rapid Insulin Eli Lilly has decided to terminate its partnership with Adocia for the development of BioChaperone Lispro, an ultra-rapid insulin for… January 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2016Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review. Given the rates of diabetes reaching 'epidemic proportions', we figured it was time to have a better overview of biotech's… June 14, 2016 - 9 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 9 Nov 2015This French Biotech has a ‘Super-Insulin’ up its Diabetes Sleeve Human insulin produced in Bacteria is already a miracle for Diabetes...but sometimes, it’s not as efficient as it could be.… November 9, 2015 - 3 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2015Is Adocia & Eli Lilly’s treatment the new diabetes blockbuster? Adocia and Eli Lilly completed an impressive Phase Ib clinical trial evaluating BioChaperone Lispro, a treatment designed to accelerate insulin… July 1, 2015 - 2 minutesmins - By Lourdes Riquelme Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2014French Biotech Start-up Adocia signs Massive €464M Diabetes Deal with Eli Lilly The French biotechnology company Adocia entered into an alliance with the US Eli Lilly on the co-development of an ultra-fast… December 20, 2014 - 2 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2014Adocia launches a Phase III in India for its Diabetic Foot Ulcer treatment Adocia announced today the initiation of a clinical Phase III study in India of BioChaperone PDGF-BB, the company’s innovative formulation… August 26, 2014 - 3 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email